Loring Wolcott & Coolidge Fiduciary Advisors’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-34
Closed -$5.76K 609
2022
Q4
$5.76K Buy
+34
New +$6.17K ﹤0.01% 527
2021
Q4
Sell
-12
Closed -$3K 763
2021
Q3
$3K Sell
12
-14
-54% -$3.59K ﹤0.01% 690
2021
Q2
$5K Buy
+26
New +$5.04K ﹤0.01% 744

Other funds holding RGEN

Loring Wolcott & Coolidge Fiduciary Advisors's RGEN Position: Q1 2023 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Repligen (RGEN) in Q1 2023, closing a stake of 34 shares — an estimated $5.76K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in RGEN in Q2 2021 and held it in 3 quarters. The position peaked at $5.76K in Q4 2022. 447 funds tracked by Wall St. Rank hold RGEN as of Q1 2023.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Repligen position as of Q1 2023 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 34 Repligen shares in Q1 2023, an estimated $5.76K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Repligen in Q2 2021 and held it in 3 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Repligen position peaked at $5.76K in Q4 2022.
  • 447 funds tracked by Wall St. Rank held Repligen as of Q1 2023.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2023, filed 2 May 2023.